Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 7, 2023; 29(1): 19-42
Published online Jan 7, 2023. doi: 10.3748/wjg.v29.i1.19
Microbiota of the gastrointestinal tract: Friend or foe?
Marina A Senchukova
Marina A Senchukova, Department of Oncology, Orenburg State Medical University, Orenburg 460000, Russia
Author contributions: Senchukova MA solely contributed to this paper.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Marina A Senchukova, MD, PhD, Professor, Department of Oncology, Orenburg State Medical University, Sovetskaya Street, Orenburg 460000, Russia.
Received: September 21, 2022
Peer-review started: September 21, 2022
First decision: October 18, 2022
Revised: November 5, 2022
Accepted: December 16, 2022
Article in press: December 16, 2022
Published online: January 7, 2023
Core Tip

Core Tip: The gut microbiota affects the development and functioning of all body systems, providing metabolic, physiological, regulatory and protective functions. Violations in the qualitative and quantitative composition of the microbiome lead to the development of a wide variety of diseases, such as diabetes, obesity, cardiovascular issues, neurological disorders and oncological concerns. Considering that intestinal dysbiosis plays a key role in the development of a number of diseases, aim to normalize the microbiome seems to be a greatly perspective direction in their prevention and treatment.